- Global Pharma News & Resources

Global DiGeorge Syndrome Drug Market Growth By 2026 ||Covid-19 Impact Analysis By Aevi Genomic Medicine, Bausch Health, Natera, Roche Sequencing, Enzyvant, Progenity, Boehringer Ingelheim International GmbH

The Report Titled on DiGeorge Syndrome Drug Market Report- Development Trends, Market Size, Industry Opportunities and Competitive Landscape in 2021 firstly introduced the – Industry.This report gives you so valuable and essentials data of Market size, share, trends, Growth, applications, forecast and cost analysis.The report takes into account the impact of the COVID-19 pandemic on the DiGeorge Syndrome Drug market and is perfect for precision and accuracy that will help to meet business requirements at affordable rates. It will help you to grow in the international Market. The study breaks market by key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume and value related cross segmented information by each country.

Get Free Sample PDF Copy (Including FULL TOC, Graphs And Tables) Of This Report @

DiGeorge Syndrome Drug Market Scenario

Global DiGeorge Syndrome Drug Market will rise from Covid-19 crisis at moderate growth rate during 2021 to 2028. DiGeorge Syndrome Drug market includes comprehensive information derived from depth study on DiGeorge Syndrome Drug Industry historical and forecast market data. Global DiGeorge Syndrome Drug market Size to expand moderately as the new developments and Impact of COVID19 over the forecast period 2020 to 2027.

Additionally, the data, facts and figures collected to get this market report are obtained forms the trustworthy sources like websites, journals, mergers, newspapers and other authentic sources. Development policies and plans are discussed also as manufacturing processes and price structures also are analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

Key Players Studied In The Global DiGeorge Syndrome Drug Market:

  • Aevi Genomic Medicine, Inc
  • Bausch Health
  • Natera, Inc
  • Roche Sequencing
  • Enzyvant, Progenity, Inc
  • Boehringer Ingelheim International GmbH
  • AbbVie Inc
  • Amgen Inc

For More Insights Get FREE Detailed TOC @

Global DiGeorge Syndrome Drug Market Scope And Market Size:-

DiGeorge syndrome is also known as 22q11.2 deletion syndrome or velocardiofacial syndrome is a rare pediatric congenital condition where children are born with absence of chromosome 22. This results to severe immunodeficiency causing poor development of several body systems. Children with DiGeorge syndrome disorders have no ability to fight against infections.

According to the article puplished in Northwestern University, it is estimated that the incident population of DiGeorge Syndrome in the United States around 500 to 750 and over 2.5 million children diagnosed yearly. These growing incidents of DiGeorge syndrome’s population worldwide and robust pipeline for development of newer therapies are the key factors for market growth.

Market Drivers

  • Vulnerable pediatric population of DiGeorge syndrome
  • Emergence of drugs for treating serious disease such as CNS disorders and cardiovascular diseases associated with DiGeorge syndrome
  • Increase in the rate of R&D initiatives is driving  DiGeorge syndrome therapeutics market

Market Restraints

  • Effective treatment is either unavailable or unaffordable
  • Patent expiry from many companies and introduction of generic drugs of branded version is expected to restrain the growth if the market
  • Inadequate knowledge about DiGeorge syndrome in some developing countries

Complete Guidance Of The Global DiGeorge Syndrome Drug Market Report:

  • The DiGeorge Syndrome Drug market report offers the most infallible and accurate data through the 360 degree research methodology.
  • While formulating DiGeorge Syndrome Drug market research report, research analyst give 24×7 support to precisely understand the business requirements.
  • With the help of SWOT analysis provided in the DiGeorge Syndrome Drug market research report, accurate intelligence can be obtained that aid business identify opportunities as well as both internal and external influences.
  • To comprehend Global DiGeorge Syndrome Drug Market dynamics in the world mainly, the worldwide DiGeorge Syndrome Drug market is analyzed across major global regions. Data Bridge Market Research also provides customized specific regional and country-level reports for the following areas.
  • Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

On The Basis Of Segmentation, The DiGeorge Syndrome Drug Market Is Primarily Divided Into:

By Route of administration

  • Oral
  • Injectable

 By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

DiGeorge Syndrome Drug Market: Regional Analysis Includes:

  • North America ( U.S., Canada and Mexico),Germany, France, U.K., Netherlands, Switzerland
  • Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC),Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India.
  • Rest of Middle East and Africa (MEA) Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia
  • Middle East and Africa (MEA), Philippines, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Argentina and Rest of South America

Key Market Players: Global DiGeorge Syndrome Drug Market

Few of the major competitors currently working in the global Digeorge syndrome drug market are Aevi Genomic Medicine, Inc, Bausch Health, Natera, Inc, Roche Sequencing, Enzyvant, Progenity, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc., Amgen Inc, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc, Angimmune LLC, Sumitomo Dainippon Pharma Co., Ltd., CELGENE CORPORATION, CELLECTAR BIOSCIENCES, INC, eFFECTOR Therapeutics, Inc., IMV Inc, Karyopharm, Neon Therapeutics, Novartis AG and many others

Key Developments in the Market:

  • In June 2019, Enzyvant’s drug candidate RVT-802, a tissue-based regenerative therapy received the FDA acceptance of Biologic License Application (BLA) as well as Priority Review status for the treatment of pediatric congenital athymia associated with complete DiGeorge Anomaly (cDGA), CHARGE syndrome, and FOXN1 deficiency. If approved, it will be the first drug used for the treatment of DiGeorge syndrome and turning it into a potential blockbuster commercial milestone for Enzyvant.
  • In September 2017, Enzyvant received Rare Pediatric Disease designation from the FDA for RVT-802, a tissue-based regenerative therapy for treatment of congenital athymia associated with complete DiGeorge Syndrome. The FDA Rare Pediatric Disease designation will enable to receive a rare pediatric disease priority review voucher upon approval of Biologic License Application (BLA).

Any Query? Enquire Here For Discount Or Report Customization:

Request A Customized Copy Of DiGeorge Syndrome Drug Report

The DiGeorge Syndrome Drug market report also covers, the trade scenario, Porter’s Analysis, Industry analysis, value chain analysis, company market share, segmental analysis.

Points Covered In Table Of Content Of Global DiGeorge Syndrome Drug Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the DiGeorge Syndrome Drug market

Chapter 2: Exclusive Summary – the basic information of the DiGeorge Syndrome Drug Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the DiGeorge Syndrome Drug

Chapter 4: Presenting the DiGeorge Syndrome Drug Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region

Chapter 6: Evaluating the leading manufacturers of the DiGeorge Syndrome Drug market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2021-2028).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source


Finally, DiGeorge Syndrome Drug Market is a valuable source of guidance for individuals and companies in decision framework.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

To Understand How Covid-19 Impact Is Covered In This Report, Get Free Covid-19 Sample @

 About Data Bridge Market Research:

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”

We provide a variety of services such as market verified industry reports, technology trend analysis, Formative market research, strategic consulting, vendor analysis, production and demand analysis, consumer impact studies among many others.

Contact Us:-           

US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email –

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 29-Jan-2021